A New Leader Joins the Fight Against Cognitive Decline—Here's Why It Matters

BrainCheck, a leading digital cognitive assessment platform, has appointed Dr. Liz Kwo to its Board of Directors, bringing decades of healthcare leadership experience to the fight against cognitive decline. Dr. Kwo's appointment comes at a critical time when cognitive impairment affects millions of Americans, and early detection tools are becoming increasingly important for managing conditions like dementia and Alzheimer's disease.

What Makes This Leadership Addition Significant?

Dr. Kwo brings an impressive combination of clinical training and business expertise to BrainCheck's mission. She holds degrees from Stanford University, Harvard Medical School, Harvard Business School, and Harvard's School of Public Health, with board certification in Preventive Medicine. Currently serving as Chief Commercial Officer at Everly Health, she oversees a $100 million profit and loss operation focused on diagnostic products and clinical innovation.

Her experience spans multiple areas of healthcare that directly impact cognitive care delivery:

• Digital Health Scaling: She helped build Amwell's online medical group and co-founded InfiniteMD, a medical second-opinion platform that was successfully acquired
• Population Health Strategy: At Anthem (now Elevance Health), she modernized health strategies across Commercial, Medicare, and Medicaid populations, focusing on digital care management
• Clinical Data Analytics: Her background includes leading clinical programs, telehealth strategy, and provider network development at major healthcare organizations

How Does This Impact Cognitive Assessment Technology?

BrainCheck's platform represents a significant advancement in how healthcare providers assess cognitive function. The company's flagship product, BrainCheck Assess, is an Food and Drug Administration (FDA) Class II-cleared digital cognitive assessment that delivers standardized, repeatable cognitive data. More than 500 healthcare organizations nationwide currently use the platform, including major health systems like Bon Secours, University of Pittsburgh Medical Center (UPMC), and Springfield Clinic.

The numbers demonstrate the platform's growing impact: over 640,000 cognitive tests and 14,000 care plans have been completed to date. Additionally, 46 research hospitals, including The University of Texas at Austin and Stanford University, use BrainCheck for cognitive research.

Why Does Early Cognitive Detection Matter Now?

"Early detection, objective assessment, and scalable care models are essential to addressing the growing burden of cognitive impairment, and BrainCheck is well-positioned to help lead that transformation," said Dr. Kwo. Her statement highlights a critical healthcare challenge: the need for accessible, reliable tools to identify cognitive changes before they progress to more severe conditions.

Traditional cognitive assessments often require specialized settings and trained neuropsychologists, creating barriers to widespread screening. Digital platforms like BrainCheck aim to democratize cognitive assessment by making it available in primary care settings and other healthcare environments where patients regularly receive care.

"Dr. Kwo brings an extraordinary combination of clinical training, operating leadership, and board-level governance expertise," said Chris Loughlin, BrainCheck's Chief Executive Officer. "Her experience scaling digital health platforms and operating across payer, provider, and technology environments will be invaluable as BrainCheck continues to grow."

As a Board of Directors member, Dr. Kwo will support BrainCheck's strategic direction, partnerships, and long-term vision to modernize cognitive assessment and care across clinical and research settings. Her appointment signals the company's commitment to expanding access to cognitive health tools at a time when the aging population increasingly needs these services.